BeiGene Co., Ltd.’s semi-annual evaluation report on the company’s 2025 “Improving Quality, Increasing Efficiency and Focusing on Returns” Action Plan

BeiGene Co., Ltd.

Regarding the company’s 2025 action plan of “improving quality, increasing efficiency and focusing on returns”

Semi-annual evaluation report

BeiGene Co., Ltd. (hereinafter referred to as the "Company") actively implements the special action of "Improving Quality, Increasing Efficiency and Focusing on Returns" for companies listed on the Science and Technology Innovation Board. The company released the "BeiGene Co., Ltd. 2025" on April 29, 2025. The annual "Improving Quality, Efficiency and Returns" Action Plan (hereinafter referred to as the "Action Plan"), in order to promote the normalization of special actions, continue the results that have been achieved, and practice the mission of "committed to being a changer in the biotechnology industry and providing effective, accessible and affordable drugs to cancer patients around the world", the company will continue to take active measures in R&D innovation, financial management, corporate governance and investor relations to further improve the company's quality, protect the rights and interests of investors, and promote the company's healthy and sustainable development.

In the first half of 2025, the implementation and progress of the main measures of the action plan and the main results are as follows:

1. Focus on the field of innovative oncology drugs and consolidate core competitiveness

The company is a world-leading innovative cancer treatment company that develops innovative anti-tumor drugs for cancer patients around the world and improves drug accessibility and affordability.

The company is a serial innovator in the hematology oncology industry and has established a differentiated, fully owned product portfolio. These include the best-in-class Bruton's tyrosine kinase (BTK) inhibitor, Sonrotoclax®, as well as two products in late-stage development, sonrotoclax (BCL2 inhibitor) and first-in-class BTK CDAC, both of which have the potential to become best-in-class drugs globally.

Baiyuez® is designed to completely and sustainably inhibit BTK, which the company believes will improve patient outcomes. This hypothesis has been supported by the results of the ALPINE trial, in which Bioza® achieved sustained superiority over ibrutinib and a lower incidence of cardiovascular toxic events in all patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). Baiyuez® is the only BTK inhibitor that has superior efficacy compared to ibrutinib. Bieze® is the most widely approved BTK inhibitor and has been approved in the United States for the treatment of patients with CLL, mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM), marginal zone lymphoma (MZL) and follicular lymphoma (FL). Although it is the third product of its kind to be approved for marketing, in less than two years after it was first approved for the treatment of CLL patients, Baiyuez® has become the leading product in the treatment of patients with new approved indications in the United States. Baiyueze® has been approved in 75 markets around the world. At the same time, the product is still in the initial stage of launch in many major markets such as Europe, Japan, South Korea and Brazil.

Sotoclax is a differentiated BCL2 inhibitor designed to be more potent and selective than venetoclax and is expected to be better tolerated. Sotocla combined with Biorex® is currently undergoing late-stage clinical trials, including the Phase 3 CELESTIAL trial of Biosex® combined with Sotocla as a fixed course of treatment for the first-line treatment of patients with CLL, which has completed enrollment. The marketing application of Sotocla for the treatment of R/R CLL and R/R MCL has been accepted in China and has been included in priority review. The company expects to submit listing applications to U.S. and other global regulatory authorities in the second half of 2025 for R/R MCL.

BTK CDAC is designed to promote the degradation of wild-type and mutant BTK (including BTK that often leads to inhibitor resistance after patient disease progression) and is currently the fastest-growing BTK degrader in clinical development. Data presented at the 2024 American Society of Hematology (ASH) Annual Meeting and the 2025 European Hematology Association (EHA) Annual Meeting show that the product has demonstrated significant early efficacy signals and safety data in patient groups who have previously received multiple lines of therapy. The company plans to initiate a Phase 3 head-to-head trial of pitubrutinib in the second half of 2025, which is consistent with the company's strategy of developing drugs that have the potential to significantly improve current treatment options. Driven by these three differentiated and synergistic products, the company believes that with its unique internal strengths, it can provide all CLL patients with the best solutions at every stage of their treatment and build a sustainable product portfolio in the $12 billion global CLL market.

In addition to its extensive presence in the field of hematological tumors, the company has a deep and innovative solid tumor product pipeline. The company's goal is to build depth in the most common cancer areas including breast/gynecological cancers, lung cancers and gastrointestinal cancers. The company continues to advance its solid tumor pipeline products, which include next-generation CDK4 inhibitors and B7-H4 antibody drug conjugates (ADCs) for the treatment of breast/gynecological cancers, potential best-in-class pan-KRAS inhibitors for the treatment of gastrointestinal (GI) cancers, differentiated mechanism of action (MoA) and first-in-class EGFR CDACs for the treatment of lung cancer, and potential best-in-class PRMT5 and MAT2A inhibitor combinations with synergistic effects for the treatment of lung cancer. In addition, the company has a number of exciting products that are still in early stages, including CDK2 inhibitors, B7-H3ADC, CEA-ADC, FGFR2bADC, EGFRxMETxMET trispecific antibodies, and IRAK4 CDAC.

The company has one of the largest preclinical oncology research teams in the industry and is strong in the translational discovery of small molecule and antibody drugs, including three independently developed platform technologies: antibody drug conjugates (ADCs), multispecific antibodies and chimeric degradation-activating compounds (CDACs). The company expects to conduct multiple proof-of-concept data readouts this year across its broad portfolio of antibody drug conjugates, multispecific antibodies and targeted protein degraders. Over the next 18 months, the company expects to achieve more than 20 milestones in its hematological and solid tumor pipelines.

Since its founding in 2010, the company has grown into a fully integrated global organization with more than 11,000 employees.

In the first half of 2025, the company achieved excellent financial performance. The main highlights are as follows:

In the first half of 2025, product revenue was 17.360 billion yuan, compared with 11.908 billion yuan in the same period last year. The growth in product revenue was mainly due to the sales growth of the independently developed product Baiyuez® (zanubrutinib capsules) and Amgen authorized products, as well as Baizuan® (tislelizumab injection).

Relying on the company's global commercialization capabilities, in the first half of 2025, the global sales of Baiyueze® totaled 12.527 billion yuan, a year-on-year increase of 56.2%, further consolidating its leadership position in the field of hematological tumors. Among them, U.S. sales totaled 8.958 billion yuan, a year-on-year increase of 51.7%, mainly due to the strong demand growth of the product in all indications and the moderate benefits brought by net pricing. Leveraging its differentiated and best-in-class clinical profile, Bioza® continues to maintain its leading position in new patient market share among BTK inhibitor drugs. European sales totaled 1.918 billion yuan, a year-on-year increase of 81.4%, mainly due to the product's increased market share in all major European markets, including Germany, Italy, Spain, France and the United Kingdom. Sales in China totaled 1.192 billion yuan, a year-on-year increase of 36.5%, mainly due to the sales growth of the product in approved indications. The company continues to maintain its leading position in China's BTK inhibitor market share.

In the first half of 2025, the sales of Baizean® totaled 2.643 billion yuan, a year-on-year increase of 20.6%. The growth in sales of Bezian® was mainly due to the new patient demand brought about by the product's approval for new indications in China and its inclusion in medical insurance and the increase in the number of drugs entering hospitals. Baizian® has achieved a leading market share in China's PD-1 market.

In the second half of 2025, the company will continue to focus on the development of its main business and continuously improve its competitiveness, including the following aspects:

1. Continue to build a global oncology innovation company with a comprehensive and integrated platform

Since its establishment in 2010, the company has grown from an R&D-based biotechnology company into a fully integrated global oncology innovation company, with capabilities covering the full cycle of innovative drug development including early-stage drug discovery, preclinical research, global clinical trial operations, independent large-scale drug production and commercialization.

The company has built a highly efficient and cost-effective oncology research team of more than 1,200 scientists, which allows the company to continue to innovate and maintain market leadership. The commercial marketing approval, clinical data and cooperation projects obtained by the company all prove the company's strength. As of June 30, 2025, partnership projects generated $1.5 billion in partnership payments for the company. The company designs each research project with a differentiated biological hypothesis MoA, and has used this to create a number of commercially approved drugs, as well as a series of in-house pipelines with combination drug potential and deep capabilities in major tumor types. The company's investments in multiple technology platforms, including CDAC protein degraders, bispecific antibodies, trispecific antibodies, and ADCs, and its ongoing pursuit of innovation enable it to leverage multiple molecule types and advance scientific progress with urgency and agility. The company's research and innovation capabilities will enable the company to bring high-quality and impactful medicines to patients in a high-throughput and cost-effective manner.

The company has established global clinical development capabilities. The company has established a large-scale global clinical team of more than 3,700 people on six continents around the world, allowing the company to conduct clinical trials without relying on CROs. The company believes that breaking free from the constraints of the traditional CRO model will allow it to conduct global clinical development activities in a more cost-effective manner and shorten clinical proof-of-concept time. At the same time, this also allows the company to expand the reach of clinical research sites, support diverse patient participation, and collect reliable data across all patient populations. The company has demonstrated the ability to complete large-scale, multi-region clinical trials, which is an important strategic competitive advantage for the company and can solve the huge challenges facing the pharmaceutical industry.

The company has established advanced in-house production capabilities. The company has established production bases for small molecule drugs and large molecule biopharmaceuticals in Suzhou and Guangzhou, China, respectively, to support the commercialization and future potential demand of the company's independently developed products or licensed products. The company's production facilities in Suzhou include a small molecule formulation production base with an annual production capacity of approximately 600 million tablets and capsules. The company has advanced commercial-scale production facilities for large molecule biologics in Guangzhou and is equipped with state-of-the-art ADC production facilities. The total production capacity can now reach 65,000 liters. In July 2024, the company officially opened its clinical R&D and biopharmaceutical production flagship base in New Jersey, USA. The base's production capacity of large molecule biopharmaceuticals can reach 8,000 liters. The Company also enters into commercial contract manufacturing agreements with contract manufacturing service providers. With in-house production capabilities and ongoing collaboration with global contract manufacturing service providers, the company will continue its strategy of diversifying its global supply network and maintaining adequate inventories of safe products.

The company has a global commercialization team to provide medicines to patients around the world. The company has established commercialization capabilities in major large-scale commercialization markets such as the United States, the European Union and China, and continues to rapidly expand its business in Asia Pacific, Latin America and the Middle East, thereby providing efficient and differentiated drugs to patients around the world. This has allowed the company to geographically diversify its revenue streams and build a truly global presence. The company has built a strong commercialized product portfolio, with Byzantine® and Byzantine® driving global revenue growth.

2. The core products independently developed have been approved for marketing in many countries and regions around the world, and the company will continue to explore the global market.

The company has three self-developed anti-tumor products approved for marketing, which have significant commercial potential.

The company's independently developed BTK inhibitor Baiyueze® is the BTK inhibitor with the most widely approved indications in the world. It is also the only BTK inhibitor with flexible dosing that can be administered once or twice daily. To date, the clinical development program of Baiyueze® has carried out more than 35 trials in more than 30 countries and regions around the world, enrolling more than 7,000 patients. The company continues to expand the global pharmaceutical registration project of Baiyueze®, and Baiyueze® has been approved in 75 markets around the world. The new film-coated tablet dosage form of Baiyueze® has been approved by the US FDA and the European Commission (EC) for all approved indications.

Trizax® is a cornerstone product of the company's solid tumor portfolio and has shown potential across a variety of tumor types and disease areas. To date, the clinical development program of Baizan® has carried out 70 trials in 35 countries and regions around the world, including 22 registered studies, enrolling more than 14,000 subjects. The company continues to expand the global pharmaceutical registration project of TALZAN®. TALIZAN® has currently been approved in 47 markets around the world, including the United States, the European Union, China, and Japan.

In the future, the company will continue to promote the approval of indications under development and further enhance the market share of commercial products through its strong clinical development capabilities and global commercial sales capabilities, maximizing the commercialization potential of the above products.

3. Continue to develop a pipeline of drug candidates with abundant reserves, leading progress, and rapid expansion to promote long-term growth.

The company continues to advance the global clinical layout and progress of its new generation of independently developed pipeline products at full speed. The company's portfolio strategy emphasizes rapid generation of early clinical proof-of-concept data, driven by the speed and cost advantages of the company's global development operations model ("rapid proof-of-concept"). The company's global research and development (including clinical operations and development) team of more than 3,700 people conducts trials on six continents and is committed to ensuring data quality meets rigorous standards by collaborating with regulatory agencies and researchers in more than 45 countries. This strategic R&D model is data-driven, allowing companies to quickly invest resources in the most promising, clinically differentiated candidate projects and adjust the priorities of other projects to maximize the use of resources. The company has one of the largest oncology research teams in the industry and is strong in the translational discovery of small molecule and antibody drugs, including three independently developed platform technologies: antibody drug conjugates (ADCs), multispecific antibodies and chimeric degradation-activating compounds (CDACs). The company expects to conduct multiple proof-of-concept data readouts this year across its broad portfolio of antibody drug conjugates, multispecific antibodies and targeted protein degraders. In the next 18 months, the company expects to achieve more than 20 milestones in its hematological and solid tumor pipelines. For late-stage clinical pipeline products, the company plans to launch a Phase III trial of the subcutaneous formulation of Tarzan® in the second half of 2025, as well as a Phase III clinical trial of BGB-16673 (BTK CDAC) to compare the non-covalent BTK inhibitor pitobrutinib (pirtobrutinib) "head-to-head" for the treatment of patients with R/R CLL. For breast cancer, the company expects to launch two phase 3 clinical trials of BGB-43395 (CDK4 inhibitor) in 2026 for the first-line and second-line treatment of hormone receptor-positive, HER2-negative metastatic breast cancer.

The company held an Investor R&D Day event in June 2025 to showcase the significant progress made by the company's industry-leading oncology treatment pipeline to global investors. This event is held during a critical period of the company's development. The company currently has more than 40 products in clinical development and commercialization stages, demonstrating the company's R&D pipeline scale, strength and development ambition.

4. Reach strategic cooperation with world-renowned pharmaceutical companies to further expand product pipeline and product layout*

The company's all-round integrated innovative drug development capabilities have been widely recognized by the industry, and it has established strategic partnerships with well-known biotechnology or pharmaceutical companies at home and abroad, which has greatly enriched the company's commercialization and research product pipelines and provided more driving factors for the company's future development. In 2017, the company reached a cooperation with Celgene Corporation (now part of Bristol-Myers Squibb) and was granted exclusive authorization to distribute and promote three approved cancer treatment drugs in mainland China. The company entered into a cooperation agreement with Amgen at the end of 2019 to be responsible for the commercialization of Amgen's anti-cancer products Angarvi®, Peritus® and Kelos® in mainland China, and to cooperate on the global development and Chinese commercialization of a series of Amgen's clinical and preclinical anti-cancer pipeline products. In January 2020, the company entered into a cooperation agreement with EUSA (acquired by Recordati), granting the company the rights to develop and commercialize Savinco® in Greater China and the exclusive right to develop and commercialize Kaiserba® in mainland China. In addition, the company actively promotes the development and commercialization of independently developed products globally through external licensing. In January 2021, the company announced a cooperation with Novartis on the anti-PD-1 antibody lorizumab®. In December 2021, the company expanded its cooperation with Novartis on the TIGIT inhibitor ospelimab. The company also has the right to market and promote Novartis's five anti-tumor drugs that have been approved and included in the National Medical Insurance List in China's vast market, including Teferal® (dabrafenib), Megenin® (trametinib), Victant® (pazopanib), Afinitor® (everolimus) and Xantho® (seritinib). In August 2025, the company entered into an agreement with Royalty Pharma to sell it the rights to receive royalties on global sales of Amgen's licensed collaboration product talatumumab outside of China. In addition, the company has also established cooperation with many partners such as Zymeworks, SpringWorks Therapeutics, Seagen (now part of Pfizer), Ingen Biotech, Angsheng Pharmaceuticals, CSPC Pharmaceutical Group, Biotech, and Luye Pharma. The scope of cooperation covers the research and development and commercialization of various innovative therapies such as small molecule drugs, monoclonal antibodies, bispecific antibodies, and ADCs. Through extensive R&D and commercialization cooperation, the company will be able to effectively expand its product pipeline and further expand its product layout.

*For updates on the company's cooperation with Bristol-Myers Squibb, please refer to "(2) Main business, main products or services" in "Section 3 Management Discussion and Analysis" of BeiGene Co., Ltd.'s 2025 Semi-annual Report. The company's cooperation with Novartis on lorzazan® and osporizumab has been terminated. The agreement with Novartis regarding China's vast market remains in effect.

2. Optimize financial management to reduce costs and increase efficiency

The company has always attached great importance to financial management. Through a series of measures such as setting up a financial sharing center, strengthening the construction of financial information systems, and optimizing financial accounting and budget management processes, it has continuously improved the company's financial management capabilities and profitability while adhering to compliance. The company's business continued to grow rapidly in the first half of 2025, with operating income increasing by 46% compared with the same period last year. The company achieved profitability in the first half of 2025. Compared with the loss in the same period last year, the overall profitability level continued to improve.

In terms of fund management, the company strengthens the account period management of customer accounts receivable and supplier accounts payable, continues to improve the efficiency of fund use, invests funds in projects with market prospects and is conducive to the development of the main business, and achieves reasonable and efficient use of funds. Since being listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange, the company has invested in raising funds according to the planned progress, ensuring the orderly progress of investment in drug clinical trial R&D projects, construction of R&D centers, R&D and industrialization of production bases, and construction of marketing networks. In the second half of 2025, the company will continue to strengthen the management of fundraising projects, strictly abide by the regulations on the management of raised funds, use raised funds safely, efficiently and prudently, and effectively ensure the smooth progress of fundraising projects as planned, promote the development of the company's main business, and enhance the company's core competitiveness and overall profitability.

3. Improve the level of corporate governance and improve the quality of listed companies

The company is currently a red chip enterprise incorporated under Swiss law and listed on the Nasdaq Global Select Market in the United States, the Stock Exchange of Hong Kong Limited and the Shanghai Stock Exchange Science and Technology Innovation Board. The company's current corporate governance system is mainly based on the relevant laws, regulations and rules of the company's place of registration and overseas listing place. The company has always attached great importance to the improvement and improvement of corporate governance levels, and continuously strengthened compliance management in terms of internal control systems and standardized operations. The company's general meeting of shareholders and board of directors operate independently and effectively and effectively perform their duties. The standing special committees of the company's board of directors include the audit committee, the remuneration committee, the nomination and corporate governance committee, the scientific advisory committee and the business and medical affairs advisory committee, which assist the board of directors in performing its functions in terms of audit, remuneration, nomination and corporate governance, scientific development and business and medical affairs strategy respectively. In addition, the company has appointed nine professionals as independent non-executive directors of the company to participate in decision-making and supervision and enhance the objectivity and scientific nature of the board of directors' decision-making.

In the first half of 2025, the company changed its registration place from the Cayman Islands to Switzerland (hereinafter referred to as the "continuing registration") and changed the company's English name to BeOne Medicines Ltd. (hereinafter referred to as the "English name change") by continuing to register as a joint-stock company in Switzerland and deregistering it in the Cayman Islands. The continued registration and English name change have been completed on May 27, 2025. For details, please refer to the "BeiGene Co., Ltd.'s Progress Announcement on Matters Related to the Change of the Company's Registration Place" disclosed on the Shanghai Stock Exchange website (http://www.sse.com.cn) on May 28, 2025 (Announcement Number: 2025-025).

The jurisdiction in which the company is registered has changed since the continued registration became effective, but the company's business and operations remain unchanged and the company continues to maintain its current operations in various countries. In addition, the continued registration did not have any significant impact on the operations of the company's subsidiaries.

In terms of protection of the rights and interests of domestic investors, the relevant laws and regulations of Switzerland, the place of overseas registration, will apply to matters related to corporate governance, operational standards and other matters after the company's continued registration takes effect. There are certain differences from the relevant corporate governance practices when the company was previously registered in the Cayman Islands. However, the overall level of protection of the rights and interests of domestic investors is still not lower than the requirements of domestic laws and regulations, and is in line with the requirements for the protection of the rights and interests of domestic investors in red-chip companies in the "Shanghai Stock Exchange Science and Technology Innovation Board Stock Listing Rules" and other relevant regulations.

After the continued registration takes effect, the company's listed shares will continue to be listed and traded on Nasdaq, the Stock Exchange of Hong Kong Limited and the Shanghai Stock Exchange Science and Technology Innovation Board under the trading codes "ONC", "06160" and "688235" respectively. The company will continue to comply with the regulations of the United States Securities and Exchange Commission, the rules of the Nasdaq Stock Exchange, the "Securities Listing Rules of The Stock Exchange of Hong Kong Limited" and the "Shanghai Stock Exchange Science and Technology Innovation Board Stock Listing Rules".

In the first half of 2025, the company will continue to summarize the updates to laws and regulations in the capital markets of the three places and the places where the company is registered, and pass them to directors, management and relevant business departments in a timely manner. The company organized personnel from investor relations, finance, information disclosure and other important business departments to participate in training organized by regulatory agencies, listed company associations, etc. The company will continue to help the "key few personnel" and those responsible for investor relations, information disclosure and other business operations to understand regulatory developments, improve their job performance skills, and continuously strengthen their legal compliance awareness and knowledge reserves, so as to promote the comprehensive improvement of the company's overall governance level and the company's continued standardized operations.

4. Strengthen investor communication and improve the quality of information disclosure

The company strictly abides by relevant laws and regulations, formulates and strictly implements information disclosure management and investor relations management systems, promptly announces major matters related to the company's operations to investors and the public, and ensures that information disclosure is true, accurate, complete and timely. The company's website also has an "Investor Relations" (https://sseir.beonemedicines.com) section, which contains company announcements and other information for investors to browse, providing investors with a quick channel for a more comprehensive understanding of the company. The company has set up an investor hotline, which is staffed by dedicated personnel to answer investor inquiries, and regularly communicates with investors through the SSE E interactive platform to protect the interests of small and medium-sized investors. The company regularly organizes research activities for institutional investors and announces the contents of investor research activities in strict accordance with information disclosure requirements.

The company attaches great importance to the compliance of information disclosure and always performs its information disclosure obligations in strict accordance with applicable laws, regulations and listing rules. The company will continue to carry out information disclosure based on the principles of "truth, accuracy, completeness, timeliness and fairness", improve the quality of information disclosure, and help investors better understand the value of the industry and the company.

In order to effectively protect the legitimate rights and interests of investors, in accordance with the provisions of applicable laws and regulations, the company has formulated systems such as the "Articles of Association" and "BeiGene Co., Ltd. Domestic Representative Work Rules for Information Disclosure", which can effectively ensure good communication between the company and investors, increase investors' understanding of the company, and further improve the level of corporate governance, thereby better maximizing the company's overall interests and protecting the legitimate rights and interests of investors. In the future, the company will use a variety of methods to communicate with investors in a timely, effective and in-depth manner, improve communication efficiency and reduce communication costs.

In the first half of 2025, the company continued to strengthen communication with investors and improve the quality of information disclosure through the following measures to enhance investors' understanding of the company and enhance investor confidence: 1) The company successfully held the 2024 annual performance briefing at the Shanghai Stock Exchange Roadshow Center. Through online interaction, the management interpreted the company's performance information for different reporting periods for investors, answered the main questions of investors' concerns in real time, and achieved instant two-way communication. In the first half of 2025, the company held two quarterly results conference calls. The archived replays of the live webcasts of the conferences have been uploaded to the "Investor Relations" area of ​​the company's website. The "Investor Relations Activity Record Form" has been disclosed after the meeting to facilitate shareholders to understand the main content of the performance conference calls. On June 26, 2025, the company announced significant progress in the company's industry-leading oncology treatment pipeline products at the Investor R&D Day event. In addition, based on the actual business progress and communication needs, the company held a number of business progress update meetings for institutional investors and participated in investor conferences organized by securities companies to strengthen communication and interaction with various investors, and timely released the "Investor Relations Activity Record Form" in accordance with information disclosure requirements; 2) Continue to respond to investors' consultation requests in a timely manner and listen to investors' opinions and demands through multiple channels such as investor hotlines, investor e-mails, and the Shanghai Stock Exchange E interactive platform, maintain communication and exchanges with investors, and protect the interests of small and medium-sized investors. 3) Carry out investor relations management activities with the help of new media, and regularly produce and disseminate visual content such as "One Picture to Understand" performance highlight charts, business progress reviews, and performance videos on the company's official platform to improve the readability of regular reports and improve the quality of information disclosure. 4) Continuously update the "Investor Relations" section of the company's website, including uploading presentations on performance and key investor activities to display the company's regular reports and business progress. A centralized display area for performance-related materials has been added, while investor presentation materials and appendices have been enriched, further improving the transparency of the company's information disclosure. 5) In order to actively respond to the needs of investors and improve the convenience of obtaining information, the company has also opened a WeChat mini program in the investor area to facilitate investors to obtain the above information. 6) In order to allow investors to better understand the company's operating performance and future performance prospects, the company has voluntarily disclosed an announcement on its 2025 operating performance forecast on February 28, 2025.

The company will continue to strengthen communication with investors in the second half of 2025 and further improve the quality of information disclosure.

5. Pay attention to the company’s investment value and improve investor returns

In April 2025, the company formulated the "BeiGene Co., Ltd. A-share market value management system" (hereinafter referred to as the "market value management system"), which has been reviewed and approved by the board of directors.

The "Market Value Management System" stipulates in detail the basic principles of market value management, the institutions and responsibilities of market value management, the methods and plans of market value management, monitoring and early warning mechanisms, and emergency measures. The company will operate in accordance with this system and standardize, focus on its main business, conduct steady operations, promote the improvement of operating standards and development quality, continue to actively take measures to protect the interests of investors, and on this basis, do a good job in investor relations management, enhance the quality and transparency of information disclosure, and promote the company's investment value to reasonably reflect the company's quality.

6. Implement the concept of sustainable development and promote high-quality development of the company

The company has always firmly implemented the concept of sustainable development. The company began to disclose the "Environmental, Social and Corporate Governance Report" in 2018. In the first half of 2025, the company released the "2024 Responsible Business and Sustainability Report", which demonstrates the company's roots in the key areas and primary tasks of responsible business and sustainable development; its vision to be a changemaker in the biotechnology industry and provide effective, affordable and accessible drugs to more cancer patients around the world; and its values ​​of putting patients first, innovating, collaborating without borders, and pursuing excellence.

The company will continue to implement the company's sustainable development goals and make responsible business and sustainable development one of the priorities of the company's work. The company will continue to focus on key areas, set optimization goals, achieve a win-win situation between economic and social responsibilities, and further promote the company's high-quality development.

All contents of the action plan are being implemented smoothly. The above contents are based on the evaluation of the implementation of the action plan as of August 2025. As of now, the company has not received opinions and suggestions from investors on improving the action plan; during the subsequent implementation process, the company will continue to optimize the action plan and continue to promote the implementation of the plan based on the company's actual situation and investors' concerns.

The forward-looking statements on business operations, development strategies, financial management, etc. involved in this report do not constitute the company's substantive commitment to investors. The implementation of the action plan may be affected by domestic and foreign market environments, policy adjustments and other factors in the future, and there is a certain degree of uncertainty. Investors are advised to pay attention to potential investment risks.

BeiGene Co., Ltd.

August 28, 2025